---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-030559"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2024-10-03T23:59:59+00:00"
generated_at: "2026-05-30T21:30:45.564275+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Palvella (merger target of Pieris) awarded up to $2.6M FDA grant for Phase 3 rare skin disease trial

## Summary
- FDA Office of Orphan Products Development awarded Palvella up to $2.6M over 4 years to support Phase 3 SELVA trial of QTORIN rapamycin gel for microcystic lymphatic malformations.
- Program has FDA Breakthrough Therapy and Fast Track designations; trial is single-arm, baseline-controlled.
- Grant one of seven awarded out of 51 applications in FY2024; underscores high unmet need in rare genetic skin disease.
- Positive development for Palvella, which is being acquired by Pieris Pharmaceuticals via merger announced July 23, 2024.

## SEC filing metadata
- accession: 0001437749-24-030559
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2024-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000143774924030559/0001437749-24-030559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000143774924030559/pirs20241003_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-030559
- JSON: https://secwatch.observer/filing/0001437749-24-030559.json
- Plain text: https://secwatch.observer/filing/0001437749-24-030559.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.